{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:42:49Z","timestamp":1770741769613,"version":"3.49.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Department of Pharmacokinetics & Pharmacodynamics"},{"name":"Gause Institute of New Antibiotics"},{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["18-15-00433"],"award-info":[{"award-number":["18-15-00433"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To explore whether linezolid\/daptomycin combinations can restrict Staphylococcus aureus resistance and if this restriction is associated with changes in the mutant prevention concentrations (MPCs) of the antibiotics in combination, the enrichment of resistant mutants was studied in an in vitro dynamic model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Two MRSA strains, vancomycin-intermediate resistant ATCC 700699 and vancomycin-susceptible 2061 (both susceptible to linezolid and daptomycin), and their linezolid-resistant mutants selected by passaging on antibiotic-containing medium were used in the study. MPCs of antibiotics in combination were determined at a linezolid-to-daptomycin concentration ratio (1:2) that corresponds to the ratio of 24\u2009h AUCs (AUC24s) actually used in the pharmacokinetic simulations. Each S. aureus strain was supplemented with respective linezolid-resistant mutants (mutation frequency 10\u22128) and treated with twice-daily linezolid and once-daily daptomycin, alone and in combination, simulated at therapeutic and sub-therapeutic AUC24s.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Numbers of linezolid-resistant mutants increased at therapeutic and sub-therapeutic AUC24s, whereas daptomycin-resistant mutants were enriched only at sub-therapeutic AUC24 in single drug treatments. Linezolid\/daptomycin combinations prevented the enrichment of linezolid-resistant S. aureus and restricted the enrichment of daptomycin-resistant mutants. The pronounced anti-mutant effects of the combinations were attributed to lengthening the time above MPC of both linezolid and daptomycin as their MPCs were lowered.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The present study suggests that (i) the inhibition of S. aureus resistant mutants using linezolid\/daptomycin combinations can be predicted by MPCs determined at pharmacokinetically derived antibiotic concentration ratios and (ii) T&amp;gt;MPC is a reliable predictor of the anti-mutant efficacy of antibiotic combinations as studied using in vitro dynamic models.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkab095","type":"journal-article","created":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T20:10:36Z","timestamp":1615407036000},"page":"1832-1839","source":"Crossref","is-referenced-by-count":5,"title":["Anti-mutant efficacy of antibiotic combinations: <i>in vitro<\/i> model studies with linezolid and daptomycin"],"prefix":"10.1093","volume":"76","author":[{"given":"Stephen H","family":"Zinner","sequence":"first","affiliation":[{"name":"Harvard Medical School; Department of Medicine, Mount Auburn Hospital, 330 Mount Auburn Street, Cambridge, MA 02138, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamilla N","family":"Alieva","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics & Pharmacodynamics, Gause Institute of New Antibiotics, 11 Bolshaya Pirogovskaya Street, Moscow 119021, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7588-1733","authenticated-orcid":false,"given":"Maria V","family":"Golikova","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics & Pharmacodynamics, Gause Institute of New Antibiotics, 11 Bolshaya Pirogovskaya Street, Moscow 119021, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena N","family":"Strukova","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics & Pharmacodynamics, Gause Institute of New Antibiotics, 11 Bolshaya Pirogovskaya Street, Moscow 119021, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yury A","family":"Portnoy","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics & Pharmacodynamics, Gause Institute of New Antibiotics, 11 Bolshaya Pirogovskaya Street, Moscow 119021, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander A","family":"Firsov","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics & Pharmacodynamics, Gause Institute of New Antibiotics, 11 Bolshaya Pirogovskaya Street, Moscow 119021, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,4,28]]},"reference":[{"key":"2021070808224254700_dkab095-B1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.7326\/0003-4819-138-2-200301210-00015","article-title":"Linezolid: the first oxazolidinone antimicrobial","volume":"138","author":"Moellering","year":"2003","journal-title":"Ann Intern Med"},{"key":"2021070808224254700_dkab095-B2","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1086\/423841","article-title":"Antimicrobial resistance to linezolid","volume":"39","author":"Meka","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2021070808224254700_dkab095-B3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(01)05410-1","article-title":"Linezolid resistance in a clinical isolate of Staphylococcus aureus","volume":"358","author":"Tsiodras","year":"2001","journal-title":"Lancet"},{"key":"2021070808224254700_dkab095-B4","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/jac\/dkg104","article-title":"Linezolid resistance in clinical isolates of Staphylococcus aureus","volume":"51","author":"Wilson","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2021070808224254700_dkab095-B5","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/jac\/dkh423","article-title":"Reversion to susceptibility in a linezolid-resistant clinical isolate of Staphylococcus aureus","volume":"54","author":"Meka","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"2021070808224254700_dkab095-B6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1086\/421471","article-title":"Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA","volume":"190","author":"Meka","year":"2004","journal-title":"J Infect Dis"},{"key":"2021070808224254700_dkab095-B7","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ijantimicag.2005.11.008","article-title":"Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis","volume":"27","author":"Gales","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"2021070808224254700_dkab095-B8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s15010-007-7220-7","article-title":"Emergence of linezolid resistance in a methicillin resistant Staphylococcus aureus strain","volume":"36","author":"Hentschke","year":"2008","journal-title":"Infection"},{"key":"2021070808224254700_dkab095-B9","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10156-009-0727-3","article-title":"Linezolid-resistant methicillin-resistant Staphylococcus aureus isolated after long-term, repeated use of linezolid","volume":"15","author":"Yoshida","year":"2009","journal-title":"J Infect Chemother"},{"key":"2021070808224254700_dkab095-B10","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/jac\/dkp494","article-title":"Linezolid-resistant ST36 methicillin-resistant Staphylococcus aureus associated with prolonged linezolid treatment in two paediatric cystic fibrosis patients","volume":"65","author":"Hill","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2021070808224254700_dkab095-B11","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1128\/AAC.01548-10","article-title":"Emergence of linezolid-resistant mutants in a susceptible-cell population of methicillin-resistant Staphylococcus aureus","volume":"55","author":"Ikeda-Dantsuji","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070808224254700_dkab095-B12","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1128\/AAC.04214-14","article-title":"In vitro resistance studies with bacteria that exhibit low mutation frequencies: prediction of \"antimutant\" linezolid concentrations using a mixed inoculum containing both susceptible and resistant Staphylococcus aureus","volume":"59","author":"Firsov","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070808224254700_dkab095-B13","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1093\/jac\/dkx249","article-title":"Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to linezolid in an in vitro dynamic model","volume":"72","author":"Firsov","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2021070808224254700_dkab095-B14","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1128\/JCM.43.10.5384-5387.2005","article-title":"Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin","volume":"43","author":"Vikram","year":"2005","journal-title":"J Clin Microbiol"},{"key":"2021070808224254700_dkab095-B15","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1086\/428616","article-title":"Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia","volume":"40","author":"Mangili","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2021070808224254700_dkab095-B16","doi-asserted-by":"crossref","first-page":"5285","DOI":"10.1128\/JCM.43.10.5285-5287.2005","article-title":"Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus","volume":"43","author":"Hayden","year":"2005","journal-title":"J Clin Microbiol"},{"key":"2021070808224254700_dkab095-B17","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/jac\/dkl256","article-title":"Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy","volume":"58","author":"Mariani","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2021070808224254700_dkab095-B18","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10096-007-0455-5","article-title":"High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia","volume":"27","author":"Sharma","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2021070808224254700_dkab095-B19","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1128\/JCM.00660-07","article-title":"Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin","volume":"46","author":"Sakoulas","year":"2008","journal-title":"J Clin Microbiol"},{"key":"2021070808224254700_dkab095-B20","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ijantimicag.2008.12.010","article-title":"Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy","volume":"33","author":"Tenover","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"2021070808224254700_dkab095-B21","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1099\/jmm.0.022533-0","article-title":"Six cases of daptomycin-non-susceptible Staphylococcus aureus bacteraemia in Singapore","volume":"59","author":"Hsu","year":"2010","journal-title":"J Med Microbiol"},{"key":"2021070808224254700_dkab095-B22","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1128\/AAC.01593-10","article-title":"Comparative genome sequencing of an isogenic pair of USA800 clinical methicillin-resistant Staphylococcus aureus isolates obtained before and after daptomycin treatment failure","volume":"55","author":"Boyle-Vavra","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070808224254700_dkab095-B23","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.diagmicrobio.2011.07.001","article-title":"Combination therapy with daptomycin, linezolid, and rifampin as treatment option for MRSA meningitis and bacteremia","volume":"71","author":"Kelesidis","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021070808224254700_dkab095-B24","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1128\/AAC.00536-10","article-title":"Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations","volume":"54","author":"Steed","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070808224254700_dkab095-B25","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1093\/jac\/dks272","article-title":"Activity of linezolid and high-dose daptomycin, alone or in combination, in an in vitro model of Staphylococcus aureus biofilm","volume":"67","author":"Parra-Ruiz","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2021070808224254700_dkab095-B26","doi-asserted-by":"crossref","first-page":"7790","DOI":"10.1128\/AAC.01604-15","article-title":"Observed antagonistic effect of linezolid on daptomycin or vancomycin activity against biofilm-forming methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model","volume":"59","author":"Luther","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070808224254700_dkab095-B27","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/jac\/dkw416","article-title":"In vitro activity of daptomycin combined with dalbavancin and linezolid, and dalbavancin with linezolid against MRSA strains","volume":"72","author":"Aktas","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2021070808224254700_dkab095-B28","doi-asserted-by":"crossref","first-page":"25.","DOI":"10.1186\/s40360-019-0305-y","article-title":"A study on combination of daptomycin with selected antimicrobial agents: in vitro synergistic effect of MIC value of 1 mg\/L against MRSA strains","volume":"20","author":"Lee","year":"2019","journal-title":"BMC Pharmacol Toxicol"},{"key":"2021070808224254700_dkab095-B29","doi-asserted-by":"crossref","first-page":"ftw019.","DOI":"10.1093\/femspd\/ftw019","article-title":"Rifampicin-containing combinations are superior to combinations of vancomycin, linezolid and daptomycin against Staphylococcus aureus biofilm infection in vivo and in vitro","volume":"74","author":"J\u00f8rgensen","year":"2016","journal-title":"Pathog Dis"},{"key":"2021070808224254700_dkab095-B30","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/1120009X.2016.1245174","article-title":"Pharmacokinetically-based prediction of the effects of antibiotic combinations on resistant Staphylococcus aureus mutants: in vitro model studies with linezolid and rifampicin","volume":"29","author":"Firsov","year":"2017","journal-title":"J Chemother"},{"key":"2021070808224254700_dkab095-B31","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijantimicag.2018.09.005","article-title":"Predicting antibiotic combination effects on the selection of resistant Staphylococcus aureus: in vitro model studies with linezolid and gentamicin","volume":"52","author":"Zinner","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2021070808224254700_dkab095-B32","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1080\/1120009X.2019.1640924","article-title":"A novel parameter to predict the effects of antibiotic combinations on the development of Staphylococcus aureus resistance: in vitro model studies at subtherapeutic daptomycin and rifampicin exposures","volume":"31","author":"Golikova","year":"2019","journal-title":"J Chemother"},{"key":"2021070808224254700_dkab095-B33","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1128\/AAC.47.2.548-553.2003","article-title":"Population pharmacokinetics of linezolid in patients treated in a compassionate-use program","volume":"47","author":"Meagher","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070808224254700_dkab095-B34","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","article-title":"Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects","volume":"47","author":"Dvorchik","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070808224254700_dkab095-B35","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0140-6736(00)04403-2","article-title":"Whole genome sequencing of meticillin-resistant Staphylococcus aureus","volume":"357","author":"Kuroda","year":"2001","journal-title":"Lancet"},{"key":"2021070808224254700_dkab095-B36","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2165\/00003088-200342130-00004","article-title":"Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial","volume":"42","author":"Stalker","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"2021070808224254700_dkab095-B37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jac\/15.suppl_A.125","article-title":"In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives","volume":"15 Suppl A","author":"Blaser","year":"1985","journal-title":"J Antimicrob Chemother"},{"key":"2021070808224254700_dkab095-B38","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ijantimicag.2008.06.031","article-title":"Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion","volume":"32","author":"Firsov","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"2021070808224254700_dkab095-B39","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1093\/jac\/dkl135","article-title":"Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration","volume":"57","author":"Olofsson","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2021070808224254700_dkab095-B40","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/jac\/dkh242","article-title":"ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model","volume":"54","author":"Firsov","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"2021070808224254700_dkab095-B41","doi-asserted-by":"crossref","first-page":"4956","DOI":"10.1128\/AAC.00578-13","article-title":"Bacterial resistance studies using in vitro dynamic models: the predictive power of the mutant prevention and minimum inhibitory antibiotic concentrations","volume":"57","author":"Firsov","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070808224254700_dkab095-B42","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ijantimicag.2014.06.013","article-title":"Predicting bacterial resistance using the time inside the mutant selection window: possibilities and limitations","volume":"44","author":"Firsov","year":"2014","journal-title":"Int J Antimicrobial Agents"},{"key":"2021070808224254700_dkab095-B43","doi-asserted-by":"crossref","first-page":"2445.","DOI":"10.3389\/fmicb.2018.02445","article-title":"Pharmacokinetic\/pharmacodynamic integration to evaluate the changes in susceptibility of Actinobacillus pleuropneumoniae after repeated administration of danofloxacin","volume":"9","author":"Zhang","year":"2018","journal-title":"Front Microbiol"},{"key":"2021070808224254700_dkab095-B44","doi-asserted-by":"crossref","first-page":"6773","DOI":"10.1128\/AAC.03505-14","article-title":"Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model","volume":"58","author":"Li","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070808224254700_dkab095-B45","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3389\/fmicb.2016.00874","article-title":"Relationship between cefquinome PK\/PD parameters and emergence of resistance of Staphylococcus aureus in rabbit tissue-cage infection model","volume":"7","author":"Xiong","year":"2016","journal-title":"Front Microbiol"},{"key":"2021070808224254700_dkab095-B46","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ja.2016.124","article-title":"Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study","volume":"70","author":"Pan","year":"2017","journal-title":"J Antibiot (Tokyo)"},{"key":"2021070808224254700_dkab095-B47","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/s41429-017-0016-9","article-title":"Time inside the mutant selection window as a predictor of staphylococcal resistance to linezolid","volume":"71","author":"Alieva","year":"2018","journal-title":"J Antibiot (Tokyo)"},{"key":"2021070808224254700_dkab095-B48","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1080\/1120009X.2018.1533267","article-title":"Concentration-dependent enrichment of resistant Enterococcus faecium exposed to linezolid in an in vitro dynamic model","volume":"30","author":"Alieva","year":"2018","journal-title":"J Chemother"},{"key":"2021070808224254700_dkab095-B49","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1128\/AAC.00502-12","article-title":"Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics","volume":"56","author":"Berti","year":"2012","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/7\/1832\/38693675\/dkab095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/7\/1832\/38693675\/dkab095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T17:04:56Z","timestamp":1625763896000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/7\/1832\/6256239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,28]]},"references-count":49,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,4,28]]},"published-print":{"date-parts":[[2021,6,18]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab095","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2021,4,28]]}}}